| Autor: |
Mellinghoff IK; Memorial Sloan Kettering Cancer Center, New York, NY, USA. MellingI@mskcc.org., Lu M; Agios Pharmaceuticals, Cambridge, MA, USA.; Mersana Therapeutics, Cambridge, MA, USA., Wen PY; Dana-Farber Cancer Institute, Boston, MA, USA., Taylor JW; University of California San Francisco, San Francisco, CA, USA., Maher EA; University of Texas Southwestern Medical Center, Dallas, TX, USA., Arrillaga-Romany I; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Peters KB; Duke University Medical Center, Durham, NC, USA., Ellingson BM; University of California, Los Angeles, Los Angeles, CA, USA., Rosenblum MK; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chun S; University of California, Los Angeles, Los Angeles, CA, USA.; California University of Science and Medicine, Colton, CA, USA., Le K; Agios Pharmaceuticals, Cambridge, MA, USA.; Aligos Therapeutics, South San Francisco, CA, USA., Tassinari A; Agios Pharmaceuticals, Cambridge, MA, USA.; Servier Pharmaceuticals LLC, Boston, MA, USA., Choe S; Agios Pharmaceuticals, Cambridge, MA, USA.; Servier Pharmaceuticals LLC, Boston, MA, USA., Toubouti Y; Agios Pharmaceuticals, Cambridge, MA, USA.; Servier Pharmaceuticals LLC, Boston, MA, USA.; Sage Therapeutics, Cambridge, MA, USA., Schoenfeld S; Agios Pharmaceuticals, Cambridge, MA, USA.; Servier Pharmaceuticals LLC, Boston, MA, USA., Pandya SS; Agios Pharmaceuticals, Cambridge, MA, USA.; Servier Pharmaceuticals LLC, Boston, MA, USA., Hassan I; Agios Pharmaceuticals, Cambridge, MA, USA.; Servier Pharmaceuticals LLC, Boston, MA, USA., Steelman L; Agios Pharmaceuticals, Cambridge, MA, USA.; Servier Pharmaceuticals LLC, Boston, MA, USA., Clarke JL; University of California San Francisco, San Francisco, CA, USA., Cloughesy TF; University of California, Los Angeles, Los Angeles, CA, USA. |
Full text from SpringerLink